Biohaven rises after completing enrollment in mid-stage obesity drug trial

Shares of drugmaker Biohaven BHVN.N rise 2% to $9.26 premarket

Co says it finished enrolling patients in a mid-stage trial for experimental obesity drug, taldefgrobep alfa,

Expects trial results in second-half of 2026

Says the injectable drug is being tested as a standalone treatment, given weekly or monthly, on overweight and obese adults

Adds the study will track changes in weight, fat and muscle mass over 24 weeks, followed by a 24-week extension to see if changes to weight and body-composition sustain or improve over a longer period

Earlier studies showed the experimental drug helped reduce fat, while preserving or increasing muscle with side effects similar to placebo

Shares fell ~70% in 2025